文献速递肝病消化道肿瘤与早癌

TBX3在CTNNB1突变型肝细胞癌中发挥抑癌作用

TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
PubMed 文献 · J Hepatol · 2021-02-10

本研究探讨TBX3在肝细胞癌(HCC)中的作用。人HCC样本中TBX3呈双峰表达:CTNNB1功能获得性突变肿瘤中高表达,非突变肿瘤中低表达。小鼠模型敲除Tbx3加速c-Met/β-catenin驱动HCC形成,机制涉及PLD1/YAP/TAZ通路,提示TBX3为抑癌基因。

要点

  • TBX3在CTNNB1突变型HCC中高表达且与分化增加相关。
  • 小鼠敲除Tbx3加速c-Met/β-catenin驱动HCC形成。
  • TBX3通过抑制PLD1降低YAP/TAZ活性发挥抑癌作用。

核心结论

  • TBX3由CTNNB1功能获得性突变诱导,通过抑制PLD1灭活YAP/TAZ从而抑制HCC生长。

研究设计与样本

  • 评估人HCC标本中TBX3表达模式。
  • 使用Tbx3flox/flox小鼠通过尾静脉注射Cre联合c-Met和ΔN90-β-catenin构建HCC模型条件性敲除Tbx3。
  • 在人HCC细胞系中过表达TBX3进行体外功能研究。

主要发现

  • 人HCC样本中TBX3呈双峰表达:CTNNB1突变肿瘤高表达,非CTNNB1突变肿瘤低表达。
  • TBX3高表达与分化增加和肿瘤生长特征降低相关。
  • Tbx3敲除显著加速c-Met/β-catenin驱动HCC形成,且Tbx3缺失HCC中YAP/TAZ活性增加。
  • 过表达LATS2可抑制YAP/TAZ活性并阻止TBX3缺失诱导的肿瘤加速生长。
  • 人HCC细胞系中过表达TBX3抑制细胞生长和YAP/TAZ活化,人HCC样本中TBX3与YAP/TAZ靶基因负相关。

临床怎么用

  • 增加TBX3表达和/或活性的策略可能对HCC治疗有效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Gain of function (GOF) mutations in the CTNNB1 gene are one of the most frequent genetic events in hepatocellular carcinoma (HCC). T-box transcription factor 3 (TBX3) is a liver-specific target of the Wnt/β-catenin pathway and thought to be an oncogene mediating activated β-catenin-driven HCC formation. METHODS: We evaluated the expression pattern of TBX3 in human HCC specimens. Tbx3 was conditionally knocked out in murine HCC models by hydrodynamic tail vein injection of Cre together with c-Met and ΔN90-β-catenin (c-Met/β-catenin) in Tbx3flox/flox mice. TBX3 was overexpressed in human HCC cell lines to investigate the functions of TBX3 in vitro. RESULTS: A bimodal expression pattern of TBX3 in human HCC samples was detected: high expression of TBX3 in GOF CTNNB1 HCC and downregulation of TBX3 in non-CTNNB1 mutant tumors. High expression of TBX3 was associated with increased differentiation and decreased expression signatures of tumor growth. Using Tbx3flox/flox mice, we found that ablation of Tbx3 significantly accelerates c-Met/β-catenin-driven HCC formation. Moreover, Tbx3(-) HCC demonstrated increased YAP/TAZ activity. The accelerated tumor growth induced by loss of TBX3 in c-Met/β-catenin mouse HCC was successfully prevented by overexpression of LATS2, which inhibited YAP/TAZ activity. In human HCC cell lines, overexpression of TBX3 inhibited HCC cell growth as well as YAP/TAZ activation. A negative correlation between TBX3 and YAP/TAZ target genes was observed in human HCC samples. Mechanistically, phospholipase D1 (PLD1), a known positive regulator of YAP/TAZ, was identified as a novel transcriptional target repressed by TBX3. CONCLUSION: Our study suggests that TBX3 is induced by GOF CTNNB1 mutants and suppresses HCC growth by inactivating PLD1, thus leading to the inhibition of YAP/TAZ oncogenes. LAY SUMMARY: TBX3 is a liver-specific target of the Wnt/β-catenin pathway and thought to be an oncogene in promoting liver cancer development. Herein, we demonstrate that TBX3 is in fact a tumor suppressor gene that restricts liver tumor growth. Strategies which increase TBX3 expression and/or activities may be effective for HCC treatment.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Liang B, Zhou Y, Qian M, et al. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis. J Hepatol. 2021. PMID: 33577921. doi:10.1016/j.jhep.2021.01.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。